MEDISCA Names Reflex Medical as Exclusive Partner for SAMIX Mixer Repair

As the sole distributor of SAMIX mixing machines to the compounding market in the United States and Canada, MEDISCA, a global leader in the personalized pharmaceutical industry, announced an exclusive partnership with Reflex Medical for all repair and servicing of SAMIX machines or otherwise known as electronic mortar and pestle mixers.

Designed for use by compounding pharmacists, the SAMIX mixer utilizes evaporation and contamination-free mixing jars that serve as a convenient and hygienic method for dispensing personalized medications. MEDISCA spent the last three years developing a partnership with SAMIX to ensure their clients across North America have access to this essential and reliable tool, and as of this week, Reflex Medical, a leading medical device manufacturer, will serve as the exclusive repair service provider for these mixers.

Reflex Medical, a Minnesota-based company founded in 2002, specializes in medical device manufacturing and design. As experts on the SAMIX machines, Reflex Medial developed the UnoDose™ Metered-Dose Topical Applicator, a versatile mixing container that doubles as a dispenser and allows the SAMIX to become a one-stop mixing solution for pharmacists.

“This three-way partnership between MEDISCA, SAMIX, and Reflex Medical enables us to provide the best possible equipment and service to our clients in North America,” said Panagiota Danopoulos, Senior Vice President at MEDISCA. “We are constantly striving to streamline and improve our clients’ operations, and we are confident that this agreement will provide the turnkey solutions our customers have come to expect from MEDISCA and its partners.”

MEDISCA also announced a special offer in connection to the partnership agreement, and as of August 1st, MEDISCA is allowing customers who have previously purchased electronic mortar and pestle machines that cannot be repaired to trade them in for a new SAMIX mixer at a reduced price. This offer can be claimed by contacting a MEDISCA sales representative.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”